ArticleFrontiers in public health2026

Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.

Lijun Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.